Extending HPV Vaccination to Age 45 Provides Small Additional Benefit
MONDAY, Dec. 9, 2019 -- Extending the current human papillomavirus (HPV) vaccination program to age 45 years is expected to produce small additional reductions in HPV-associated diseases with high additional costs, according to a study published...
Source: Drugs.com - Pharma News - Category: Pharmaceuticals Source Type: news
More News: Cervical Cancer Vaccine | Genital Warts | Human Papillomavirus (HPV) | Pharmaceuticals | Study | Vaccines